Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.33 |
| ▸ | RELA | Q04206 | 2/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7906417 | 0.91 | KCNQ1 (0.37) | MEN1KMT2ATYRKDM4EKCNQ1 | |
| SCHEMBL9890980 | 0.89 | KCNQ1 (0.42) | MEN1KMT2ATYRKCNQ1ALDH1A1 | |
| SCHEMBL7907810 | 0.81 | KCNQ1 (0.45) | MEN1KMT2ATYRKDM4EKCNQ1 | |
| SCHEMBL9890977 | 0.80 | TYR (0.39) | MEN1KMT2ATYRKDM4ENPSR1 | |
| SCHEMBL9890985 | 0.79 | TYR (0.50) | MEN1KMT2ATYRKDM4EALDH1A1 | |
| SCHEMBL15578481 | 0.75 | TYR (0.42) | MEN1KMT2ATYRKDM4EALDH1A1 | |
| SCHEMBL12732039 | 0.71 | TYR (0.38) | MEN1KMT2ATYRKDM4EALDH1A1 | |
| SCHEMBL10194576 | 0.71 | TYR (0.47) | MEN1KMT2ATYRKDM4EALDH1A1 | |
| SCHEMBL12708170 | 0.71 | TYR (0.40) | MEN1KMT2ATYR | |
| SCHEMBL12708283 | 0.69 | TYR (0.52) | MEN1KMT2ATYRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633320-B2 | Process for preparing bromo-substituted quinolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-20120165534-A1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| US-20120142929-A1 | PROCESS FOR PREPARING SULFONYL QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165534-A1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | HCCS, CYP3A7, ABL1 | MEN1 1853/4885KMT2A 3142/4885TYR 424/4885 |
| US-20120142929-A1 | PROCESS FOR PREPARING SULFONYL QUINOLINES | GYS2, CYP3A7, GBA1 | MEN1 2574/4885KMT2A 4064/4885TYR 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.